Related Experiment Videos

A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and

A Paula Simões-Wüst1, Sally Hopkins-Donaldson, Brigitte Sigrist

  • 1Molecular Oncology Laboratory, Department of Oncology, University Hospital Zurich, Zurich, Switzerland.

Oligonucleotides
|January 1, 2005
PubMed

Insights

Locked nucleic acid (LNA) oligonucleotides show enhanced ability to downregulate Bcl-2 and Bcl-xL, crucial for tumor cell survival. This LNA analog improved cancer cell apoptosis and reduced tumor cell viability more effectively than previous modifications.

Area of Science:

  • Molecular Biology
  • Anticancer Therapeutics
  • Oligonucleotide Chemistry

Background:

  • Bcl-2 and Bcl-xL are antiapoptotic proteins frequently overexpressed in human tumors.
  • Antisense oligonucleotides are a promising therapeutic strategy for targeting oncogenic gene expression.
  • Previous 2'-O-(2-methoxy)ethyl (2'-MOE)-modified gapmer antisense oligonucleotide 4625 demonstrated bispecific activity against Bcl-2 and Bcl-xL.

Purpose of the Study:

  • To evaluate the efficacy of a locked nucleic acid (LNA)-modified isosequential antisense oligonucleotide (5005) compared to a 2'-MOE-modified counterpart (4625).
  • To assess the ability of 5005 to enhance the downregulation of Bcl-2 and Bcl-xL in cancer cells.
  • To investigate the impact of 5005 on tumor cell viability and its synergistic effects with other anticancer agents.

Main Methods:

  • Design and synthesis of isosequential 2'-MOE and LNA-modified antisense oligonucleotides (4625 and 5005, respectively).
  • Assessment of gene expression downregulation of Bcl-2 and Bcl-xL in MDA-MB-231 breast and H125 lung cancer cell lines.
  • Evaluation of cell viability and apoptosis induction following antisense oligonucleotide treatment.
  • Combination studies of oligonucleotide 5005 with various anticancer agents.

Main Results:

  • Oligonucleotide 5005 demonstrated superior downregulation of the mismatching Bcl-xL target compared to 4625 in both cancer cell lines.
  • Antisense activity of 5005 led to decreased cell viability through apoptosis induction.
  • Combination therapy with 5005 showed enhanced reduction in tumor cell viability compared to 4625.
  • LNA modification improved the efficacy and target specificity of the antisense oligonucleotide.

Conclusions:

  • Isosequential LNA-modified oligonucleotide 5005 is more effective than the 2'-MOE analog 4625 in downregulating Bcl-2 and Bcl-xL.
  • LNA modifications enhance the potency and specificity of antisense oligonucleotides for cancer therapy.
  • Oligonucleotide 5005 represents a promising therapeutic candidate for targeting antiapoptotic proteins in human tumors.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...